Dosing, Treatment Cycle During Phase 2 Trial Assessing Infigratinib for Treatment of Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Pharmacy Times interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, on the phase 2 trial results that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

During this discussion, Javle addressed the dosing and treatment cycle during the trial.